Liu Ling, Wang Yongjun, Chen Hongyu, Zhu Xiaoling, Zhou Liusha, Yang Yazhen
Department of Nephrology, Hangzhou Traditional Chinese Medical Hospital , Hangzhou, Zhejiang , China.
Ren Fail. 2014 Sep;36(8):1244-52. doi: 10.3109/0886022X.2014.938544. Epub 2014 Jul 14.
Vascular calcification significantly increases the rates of cardiovascular mortality in hemodialysis (HD) patients. Abnormalities in mineral metabolism may play a role in the pathogenesis of arterial calcification. Whether patients treated with non-calcium-based phosphate binders had reduced aortic vascular calcification compared to those treated with calcium-based phosphate binders is still unclear.
We searched multiple databases for studies published through August 2013 that evaluated the effects of non-calcium-based phosphate binders (NCBP) versus calcium-based phosphate binders (CBP) on cardiovascular calcification and bone remodeling among dialysis patients. We summarized test performance characteristics with the use of forest plots, fixed and random effects models, and Egger regression test.
Eighteen eligible randomized controlled trials totaling 3676 patients were included. Meta-analysis results showed NCBP could significantly attenuate the progression of coronary artery calcification than CBP (WMD: -144.62, 95% CI: -285.62 to -3.63). The serum calcium levels significant lower in NCPB group than in CPB groups (WMD: -0.26, 95% CI: -0.37 to -0.14), but the serum iPTH levels were significantly higher in NCPB groups (WMD: 57.1, 95% CI: 13.42 to 100.78). The osteoid volume and osteoblast numbers were significant higher in NCPB group than in CPB group (WMD: 1.75, 95% CI: 0.78 to 2.73 for osteoid volume; WMD: 4.49, 95% CI: 1.83 to 7.15 for osteoblast numbers). The Egger regression test also showed no potential publication bias (p = 0.725).
Based on available data, NCBPs have equally effective with CBPs for serum phosphate control. But there was significantly lower incidence of coronary artery calcification and a significant higher bone formatting rate in NCBP groups than in CBP groups. So we recommend NCBPs as phosphate binders for HD patients.
血管钙化显著增加血液透析(HD)患者的心血管死亡率。矿物质代谢异常可能在动脉钙化的发病机制中起作用。与使用钙基磷结合剂治疗的患者相比,使用非钙基磷结合剂治疗的患者主动脉血管钙化是否减少仍不清楚。
我们检索了多个数据库,查找截至2013年8月发表的评估非钙基磷结合剂(NCBP)与钙基磷结合剂(CBP)对透析患者心血管钙化和骨重塑影响的研究。我们使用森林图、固定和随机效应模型以及Egger回归检验总结了检验性能特征。
纳入了18项符合条件的随机对照试验,共3676例患者。荟萃分析结果显示,与CBP相比,NCBP可显著减轻冠状动脉钙化的进展(加权均数差:-144.62,95%可信区间:-285.62至-3.63)。NCBP组的血清钙水平显著低于CBP组(加权均数差:-0.26,9%可信区间:-0.37至-0.14),但NCBP组的血清全段甲状旁腺激素(iPTH)水平显著更高(加权均数差:57.1,95%可信区间:13.42至100.78)。NCBP组的类骨质体积和成骨细胞数量显著高于CBP组(类骨质体积的加权均数差:1.75,95%可信区间:0.78至2.73;成骨细胞数量的加权均数差:4.49,95%可信区间:1.83至7.15)。Egger回归检验也显示无潜在的发表偏倚(P = 0.725)。
根据现有数据,NCBP在控制血清磷方面与CBP同样有效。但NCBP组的冠状动脉钙化发生率显著更低,骨形成率显著更高。因此,我们推荐将NCBP作为HD患者的磷结合剂。